Revolution Medicines (RVMD) Common Equity (2019 - 2026)

Revolution Medicines has reported Common Equity for 8 years, with the latest figure at $2.6 billion in Q2 2026.

• On a quarterly basis, Common Equity rose 39.72% year-over-year to $2.6 billion in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 39.72% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, down 27.98% from the prior year.
• Common Equity was $2.6 billion for Q2 2026 at Revolution Medicines, up from $1.5 billion in the prior quarter.
• The five-year high for Common Equity was $2.6 billion in Q2 2026, with the low at $498.8 million in Q2 2022.
• Average Common Equity over 5 years is $1.4 billion, with a median of $1.6 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Common Equity jumped 166.52% in 2023, then dropped 27.98% in 2025.
• Over 5 years, Common Equity stood at $685.2 million in 2022, then surged by 166.52% to $1.8 billion in 2023, then gained by 24.04% to $2.3 billion in 2024, then decreased by 27.98% to $1.6 billion in 2025, then soared by 59.76% to $2.6 billion in 2026.
• The last three Common Equity figures came in at $2.6 billion (Q2 2026), $1.5 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.